The offering provides a strong cash runway for a clinical-stage biotech, reducing near-term financing risk, but the dilution is material. Monitor upcoming clinical data readouts for JADE101 (APRIL-targeting in IgA nephropathy) as the primary catalyst; the cash extends the runway but does not change the binary risk of pipeline failure.
Price Chart
Executive Summary
Jade Biosciences closed a public offering of 11.5M shares at $15.00/share, raising $172.5M in gross proceeds. The proceeds will fund clinical trials, preclinical studies, and manufacturing for its autoimmune pipeline, including lead candidate JADE101 for IgA nephropathy. The offering represents significant dilution (~13% of pre-offer shares based on market cap) but provides a substantial cash runway for a clinical-stage biotech.
Key Financial Metrics
Key Facts
- Closed public offering of 11,500,000 shares at $15.00 per share
- Gross proceeds of $172.5 million
- Underwriters' option for 1,500,000 additional shares fully exercised
- Offered under shelf registration statement on Form S-3 effective May 15, 2026
- Proceeds to fund clinical trials, preclinical studies, manufacturing, R&D, and general corporate purposes
- Lead candidate JADE101 targets APRIL for IgA nephropathy; pipeline includes JADE201 (anti-BAFF-R) and JADE301 (undisclosed)
Financial Impact
Dilution of approximately 13% based on pre-offering market cap of $876M; $172.5M gross proceeds added to cash balance
Risk Factors
- Significant dilution to existing shareholders (~13%)
- Clinical-stage company with no approved products; pipeline risk is binary
- Proceeds used for general corporate purposes, not tied to specific near-term catalyst
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307597 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | 8-K | $14.05 $13.77 | ▼ −1.99% | ▼ −3.91% | $14.50 (+3.20%) |
Aug 10, 2026 11w ago | 8-K | $21.73 $23.45 | ▲ +7.92% | ▲ +7.96% | $14.50 (−33.27%) |
Aug 10, 2026 11w ago | Press Release | $21.73 $23.45 | ▲ +7.92% | ▲ +7.96% | $14.50 (−33.27%) |
Jun 5, 2026 20w ago | Press Release | $14.98 $16.10 | ▼ −7.48% | ▼ −5.37% | $14.50 (+3.20%) |
Jun 4, 2026 20w ago | 8-K | $16.94 $15.34 | ▲ +9.45% | ▲ +10.01% | $14.50 (+14.40%) |
Jun 4, 2026 20w ago | 424B5 | $16.94 $15.34 | ▲ +9.45% | ▲ +10.01% | $14.50 (+14.40%) |
Jun 3, 2026 20w ago | Press Release | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 3, 2026 20w ago | 424B5 | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 3, 2026 20w ago | Press Release | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 1, 2026 21w ago | 8-K | $18.59 $16.94 | ▼ −8.88% | ▼ −6.13% | $14.50 (−22.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers